

# NHF BENEFITS UPDATE

The following changes have been made to the  
**NHF DRUG LIST EFFECTIVE MAY 18, 2022.**

ILLNESS	ACTIVE PHARMACEUTICAL INGREDIENT	PROPRIETARY NAME	SUBSIDY	TYPE OF CHANGE
ARTHRITIS/LUPUS	RITUXIMAB	MABTHERA INJECTION 500MG/50ML - 1 VIAL	\$66,165.00	NEW LABEL NAME
HYPERTENSION	PERINDOPRIL /INDAPAMIDE /AMLODIPINE	TRIPLIXAM TABLETS 5MG/1.25MG/10MG - 30S	\$95.55	NEW STRENGTH
VASCULAR/ SICKLE CELL DISEASE	DIOSMIN/HESPERIDIN	DAFLON TABLETS 1000MG - 36S	\$37.86	NEW PACK SIZE

